GPR119 agonist 5
GPR119 agonist 5 is an orally active GPR119 agonist with EC50=12.6 nM. GPR119 agonist 5 activates the Gs-cAMP signaling pathway and promotes GLP‑1, GIP, and glucose-dependent insulin secretion. GPR119 agonist 5 lowers blood glucose and increases plasma insulin and glucagon-like peptide levels in mice, and improves glycemic control and reduces glycated hemoglobin in diabetic rats. GPR119 agonist 5 can be used for research on type 2 diabetes.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 1782102-85-5
- 화학식: C30H40F2N4O4
- 분자량:558.66
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO-K1 | EC50 |
12.6 nM
|
GPR119 agonist activity in T-Rex GPR119 CHO-K1 DA cells assessed as cAMP production by FRET assay with 5 hrs compound incubation.
GPR119 agonist activity in T-Rex GPR119 CHO-K1 DA cells assessed as cAMP production by FRET assay with 5 hrs compound incubation.
|
acs.jmedchem.6c02105 |
In Vitro
GPR119 agonist 5 shows negligible inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in human liver microsomes, with IC50 >15 μM[1].
GPR119 agonist 5 is stable in mouse, monkey, and human liver microsomes, with remaining amounts of 95.8%, 96.9%, and 94.7%, respectively[1].
GPR119 agonist 5 shows no significant hERG channel inhibition in automated patch-clamp experiments, with an IC50 >100 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Parmacokinetics
| Species | Dose | Route | AUC | T1/2 | Vdss | Cmax | Tmax | F |
|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.v. | 12,182 ng·h/mL | 2.9 h | 3522 L/kg | / | / | / |
| Mice[1] | 10 mg/kg | p.o. | 13,713 ng·h/mL | 2.6 h | / | 2,261 ng/mL | 0.5 h | 112 % |
| Cynomolgus Monkey[1] | 1 mg/kg | i.v. | 1668 ng·h/mL | 4.4 h | 3252 L/kg | / | / | / |
| Cynomolgus Monkey[1] | 10 mg/kg | p.o. | 11,431 ng·h/mL | 6.0 h | / | 1502 ng/mL | 2.0 h | 68.5 % |
In Vivo
GPR119 agonist 5 (1 mg/kg; p.o.; QD; single administration) improves glucose tolerance in ZDF rats on day 1, and its combination with Sitagliptin (HY-13749) reduces blood glucose by 32%[1].
GPR119 agonist 5 (1 mg/kg; p.o.; QD; 49 days) reduces HbA1c to 7% after 49 days of administration in ZDF rats, and combined administration with Sitagliptin reduces blood glucose by 41% at day 28[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Zucker Diabetic Fatty (ZDF) (female, 7 weeks old at dosing, provided with 60% high fat diet)[1]
-
Dosage:1 mg/kg (single)
1 mg/kg combined with Sitagliptin (HY-13749) at 5 mg/kg -
Administration:p.o.; QD; single administration
-
Result:Lowered day-1 blood glucose during oGTT to a similar extent as sitagliptin at 5 mg/kg.
The combination with sitagliptin at 5 mg/kg reduced blood glucose by 32% versus vehicle at day 1.
No meaningful day-1 HbA1c change was observed.
-
Animal Model:Zucker Diabetic Fatty (ZDF) (female, 7 weeks old at dosing, provided with 60% high fat diet)[1]
-
Dosage:1 mg/kg (single)
1 mg/kg combined with Sitagliptin at 5 mg/kg -
Administration:p.o.; QD; 49 days
-
Result:Reduced HbA1c to 7% at day 49.
Long-term combined administration with sitagliptin at 5 mg/kg for 28 days reduced blood glucose by 41% versus vehicle, exceeding the effect of sitagliptin alone.
Chemical Information
-
CAS No. 1782102-85-5
-
분자량 558.66
-
화학식 C30H40F2N4O4
-
SMILES
O=C(C1=C(C=C(C2=CC=C(C=N2)OCC3CCN(CC3)CC(CC)(F)CC)C=C1)F)N4[C@@](C)(C[C@H](C4)O)C(N)=O
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)